Contralateral eye comparison study in MIGS: Trabectome® vs iStent Inject®

Session Details

Session Title: Glaucoma II

Session Date/Time: Tuesday 08/09/2015 | 08:00-10:30

Paper Time: 08:24

Venue: Room 17

First Author: : J.Gonnermann GERMANY

Co Author(s): :    M. Klamann   A. Maier   M. Pahlitzsch   N. Torun   E. Bertelmann        

Abstract Details

Purpose:

To compare the safety and efficacy profile after micro-invasive glaucoma surgery (MIGS) with ab interno trabeculectomy (Trabectome®) in one eye versus two iStent® inject decives in the contralateral eye in patients with open-angle glaucoma (OAG).

Setting:

Department of Ophthalmology, Charité-Universitätsmedizin, Berlin

Methods:

This study included 20 patients who were treated with ab interno trabeculectomy (group I, Trabectome®) in one eye and with two iStent® inject decives (group II, GTS 400) in the fellow eye. Primary outcome measures included intraocular pressure (IOP) and glaucoma medication after 6 weeks, 3 months and 6 months follow-up. Secondary outcome measures were number of postoperative interventions, complications and best-spectacle corrected visual acuity.

Results:

Mean preoperative IOP was 23.0 ± 3.8 mmHg in group I and 22.4 ± 5.5 mmHg in group II (P>0.05), which decreased to 14.3 ± 3.3 mmHg for Trabectome (P<0.05) and 14.6± 2.3 mmHg for iStent inject (P<0.05) at 6 months after surgery without a significant difference between the two groups (P>0.05). Glaucoma medication decreased from 2.2 ± 1.2 in group I and 2.3 ± 1.0 in group II (P>0.05) before surgery to 1.8 ± 1.0 in group I and 1.9 ± 1.2 6 months postoperatively (P>0.05). Intraoperative blood reflux occurred in 100% of cases. No postoperative vision-threatening complications occurred. In each group trabeculectomy had to be performed in 2 eyes due to insufficient IOP lowering effect of MIGS.

Conclusions:

Ab interno trabeculectomy (Trabectome®) and iStent® inject were both effective in lowering IOP with a favourable and comparable safety profile in an intraindividual comparative study over a 6-month follow up in OAG. However, longer follow-up of these patients will be necessary to determine long-term outcomes and to evaluate significant differences.

Financial Interest:

NONE